Incyte Corporation (NASDAQ:INCY) was downgraded by investment analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Friday.

INCY has been the topic of several other research reports. Oppenheimer Holdings, Inc. set a $125.00 price target on Incyte Corporation and gave the company a “hold” rating in a research note on Thursday, May 18th. BMO Capital Markets boosted their price objective on Incyte Corporation from $144.00 to $146.00 and gave the company an “outperform” rating in a report on Friday, May 5th. TheStreet cut Incyte Corporation from a “b-” rating to a “c+” rating in a report on Monday, April 17th. Credit Suisse Group set a $167.00 price objective on Incyte Corporation and gave the company a “buy” rating in a report on Wednesday, April 19th. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $148.00 price objective (down previously from $165.00) on shares of Incyte Corporation in a report on Monday, April 17th. Seven analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. Incyte Corporation presently has an average rating of “Buy” and an average target price of $140.39.

Incyte Corporation (INCY) traded up 2.56% on Friday, reaching $132.00. The company’s stock had a trading volume of 1,038,399 shares. The firm’s 50 day moving average price is $130.23 and its 200-day moving average price is $129.04. The company’s market capitalization is $27.15 billion. Incyte Corporation has a 1-year low of $75.52 and a 1-year high of $153.15.

Incyte Corporation (NASDAQ:INCY) last posted its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The firm had revenue of $326.40 million for the quarter, compared to analysts’ expectations of $318.45 million. Incyte Corporation had a negative net margin of 11.77% and a negative return on equity of 21.57%. The firm’s revenue for the quarter was up 32.5% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.18 EPS. Equities analysts forecast that Incyte Corporation will post ($0.77) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally published by Daily Political and is owned by of Daily Political. If you are viewing this piece of content on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright legislation. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/07/incyte-corporation-nasdaqincy-rating-lowered-to-hold-at-bidaskclub.html.

In related news, Director Jean Jacques Bienaime purchased 500 shares of the company’s stock in a transaction dated Monday, May 15th. The stock was acquired at an average cost of $115.00 per share, for a total transaction of $57,500.00. Following the completion of the transaction, the director now directly owns 4,177 shares of the company’s stock, valued at $480,355. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Eric H. Siegel sold 1,820 shares of the company’s stock in a transaction that occurred on Tuesday, August 1st. The shares were sold at an average price of $132.92, for a total value of $241,914.40. Following the completion of the sale, the executive vice president now owns 23,553 shares of the company’s stock, valued at $3,130,664.76. The disclosure for this sale can be found here. Insiders have sold 45,183 shares of company stock valued at $5,601,196 in the last three months. Insiders own 17.70% of the company’s stock.

Several large investors have recently bought and sold shares of INCY. Macquarie Group Ltd. raised its stake in Incyte Corporation by 156.6% in the fourth quarter. Macquarie Group Ltd. now owns 107,073 shares of the biopharmaceutical company’s stock worth $10,736,000 after buying an additional 65,344 shares during the period. Chevy Chase Trust Holdings Inc. bought a new stake in Incyte Corporation during the first quarter worth about $20,298,000. CT Financial Advisors LLC raised its stake in Incyte Corporation by 4.7% in the first quarter. CT Financial Advisors LLC now owns 10,742 shares of the biopharmaceutical company’s stock worth $1,436,000 after buying an additional 481 shares during the period. Douglass Winthrop Advisors LLC bought a new stake in Incyte Corporation during the first quarter worth about $201,000. Finally, Exxonmobil Investment Management Inc. TX bought a new stake in Incyte Corporation during the first quarter worth about $5,229,000. Institutional investors and hedge funds own 91.73% of the company’s stock.

About Incyte Corporation

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Analyst Recommendations for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.